Hatch BioFund Announces Investment in Optimeos Life Sciences to Advance Novel Nanoparticle Platform for the Delivery of Therapeutic Nucleic Acids and Proteins
Hatch BioFund, an early-stage life sciences venture capital firm headquartered at the Pennsylvania Biotechnology Center in Doylestown, PA ("Hatch"), today announced an investment in Optimeos Life Sciences, Inc., a Princeton University spinout developing a proprietary nanoparticle platform for the intracellular delivery of therapeutic macromolecules, including RNA, DNA and proteins (“Optimeos”).
